SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ARWR

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

US · Delayed Price · Currency is USD
Also listed: 0HI3.LHealthcare · Biotechnology
$41.37-$2.28 (-5.22%)
 
Market cap
$5.85B
Insider Score
Health Score
Analyst consensus
Listed since
Dec 16, 1993
Market Cap$5.85B-6.5%
Revenue (ttm)$450.82M-45.6%
Net Income-$724.20M-44302.3%
EPS-$5.09-7171.4%
Shares Out141.37M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,906,214
Open$43.36
Previous Close$43.65
Day's Range$41.17 - $44.71
52-Week Range$40.43 - $95.49
Beta1.37
AnalystsBuy
Price Target$111.20(+168.79%)
Earnings DateFeb 4, 2027

About ARWR

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Address
177 East Colorado Boulevard, Pasadena, CA, 91105, US
Market Cap
5.85 billion
Employees
1,059
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$8.41M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
3 Buy0 Hold0 SellAvg target $93.57 (+126.2%)

3 firms rating ARWR in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From ARWR’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.22%
5 Days
-12.20%
1 Month
-29.11%
6 Months
-44.80%
1 Year
-6.53%

$ARWR stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ARWR holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ARWR's directors and management

Net Shares Purchased by Insiders−90k−45k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ARWR Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ARWR Revenue by Segment

$1.32BTotal
Collaboration and license revenue$444.21M33.72%
Candidate costs$443.22M33.65%
Acquired Priority Review Voucher$215.00M16.32%
Professional, outside services, and other$92.58M7.03%
Discovery costs$78.84M5.99%
Facilities related$31.07M2.36%
Product revenue, net$6.60M0.50%
Other, net$3.98M0.30%
Cost of product revenue$1.80M0.14%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-K)

U.S. Patents

New ARWR patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ARWR from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ARWR

IJHiShares Core S&P Mid-Cap ETF$210.55M
VTIVanguard Morningstar Total Stock Market ETF$201.79M
VBVanguard Morningstar Small-Cap ETF$180.20M
VBKVanguard Morningstar Small-Cap Growth ETF$100.88M
VXFVanguard Extended Market ETF$96.00M
XBIState Street SPDR S&P Biotech ETF$80.01M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ARWR’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
45

News check: Mixed coverage: REDEMPLO opportunity and commercial momentum offset by earnings miss and widening losses.

Recent Insider Activity

Buys
0
Sells
20
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

THNRAmplify Weight Loss Drug & Treatment ETF2.78%
HLTHTema Healthcare AI ETF2.55%
GNOMGlobal X - Genomics & Biotechnology ETF1.97%
FRTYAlger Mid Cap 40 ETF1.88%
RFGInvesco S&P MidCap 400 Pure Growth ETF1.58%
XMMOInvesco S&P MidCap Momentum ETF1.30%
TDNAT. Rowe Price Biotech ETF1.24%
GNMXCorgi ETF Trust I - Corgi Genomics & Precision Medicine ETF1.12%
HTECROBO Global Healthcare Technology and Innovation ETF1.05%
WDNAWisdomTree BioRevolution Fund0.96%
XBIState Street SPDR S&P Biotech ETF0.85%
BBPVirtus Biotech ETF0.85%

Weight is the stock’s share of each fund’s holdings.